These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7964692)

  • 1. Cholinergic approaches to the treatment of progressive supranuclear palsy.
    Litvan I
    J Neural Transm Suppl; 1994; 42():275-81. PubMed ID: 7964692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.
    Foster NL; Aldrich MS; Bluemlein L; White RF; Berent S
    Neurology; 1989 Feb; 39(2 Pt 1):257-61. PubMed ID: 2644580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physostigmine treatment of progressive supranuclear palsy.
    Litvan I; Gomez C; Atack JR; Gillespie M; Kask AM; Mouradian MM; Chase TN
    Ann Neurol; 1989 Sep; 26(3):404-7. PubMed ID: 2802540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?
    Blin J; Mazetti P; Mazoyer B; Rivaud S; Ben Ayed S; Malapani C; Pillon B; Agid Y
    Brain; 1995 Dec; 118 ( Pt 6)():1485-95. PubMed ID: 8595479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study.
    Frattali CM; Sonies BC; Chi-Fishman G; Litvan I
    Dysphagia; 1999; 14(3):165-8. PubMed ID: 10341115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy.
    Kertzman C; Robinson DL; Litvan I
    Arch Neurol; 1990 Dec; 47(12):1346-50. PubMed ID: 2252453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic systems in progressive supranuclear palsy.
    Warren NM; Piggott MA; Perry EK; Burn DJ
    Brain; 2005 Feb; 128(Pt 2):239-49. PubMed ID: 15649952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
    Atack JR; Litvan I; Thal LJ; May C; Rapoport SI; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 Sep; 54(9):832-5. PubMed ID: 1955905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pedunculopontine tegmentum cholinergic loss leads to a progressive decline in motor abilities and neuropathological changes resembling progressive supranuclear palsy.
    MacLaren DAA; Ljungberg TL; Griffin ME; Clark SD
    Eur J Neurosci; 2018 Dec; 48(12):3477-3497. PubMed ID: 30339310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of progressive supranuclear palsy].
    Finali G; Piccinin GL; Piccirilli M; Stefano E
    Clin Ter; 1989 Jun; 129(5):339-51. PubMed ID: 2569956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil in the treatment of progressive supranuclear palsy.
    Fabbrini G; Barbanti P; Bonifati V; Colosimo C; Gasparini M; Vanacore N; Meco G
    Acta Neurol Scand; 2001 Feb; 103(2):123-5. PubMed ID: 11227131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy for progressive supranuclear palsy: past and future.
    Cole DG; Growdon JH
    J Neural Transm Suppl; 1994; 42():283-90. PubMed ID: 7964693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward future therapies in progressive supranuclear palsy.
    Burn DJ; Warren NM
    Mov Disord; 2005 Aug; 20 Suppl 12():S92-8. PubMed ID: 16092097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
    Litvan I; Mangone CA; McKee A; Verny M; Parsa A; Jellinger K; D'Olhaberriague L; Chaudhuri KR; Pearce RK
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):615-20. PubMed ID: 8648326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis.
    Liepelt I; Gaenslen A; Godau J; Di Santo A; Schweitzer KJ; Gasser T; Berg D
    Alzheimers Dement; 2010 Jan; 6(1):70-4. PubMed ID: 20129321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with rotigotine in drug-naïve PSP patients.
    Schirinzi T; Pisani V; Imbriani P; Di Lazzaro G; Scalise S; Pisani A
    Acta Neurol Belg; 2019 Mar; 119(1):113-116. PubMed ID: 30062400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.
    Nuebling G; Hensler M; Paul S; Zwergal A; Crispin A; Lorenzl S
    J Neurol; 2016 Aug; 263(8):1565-74. PubMed ID: 27230855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pramipexole in progressive supranuclear palsy.
    Weiner WJ; Minagar A; Shulman LM
    Neurology; 1999 Mar; 52(4):873-4. PubMed ID: 10078747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of Treatment Options for Progressive Supranuclear Palsy.
    Stamelou M; Höglinger G
    CNS Drugs; 2016 Jul; 30(7):629-36. PubMed ID: 27222018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.